top of page




WP1 will assess the availability and quality of published evidence about the burden of drug-resistant bacterial infections, in a healthcare context.

We will extract high-quality data to summarize and extrapolate frequency measures, and health and economic outcomes of interventions, as well as to parametrise the mathematical models aiming to estimate the possible impact of interventions.


  1. Prepare a systematic review of protocols and systematically review the available evidence from scientific literature, grey literature, and websites, including quality assessment of the available evidence and, if possible, meta-analysis of measures, on:

    • ​AMR case definition and AMR frequency measures

    • Aggregated data on AMR-associated health outcomes

    • AMR-associated economic outcome

  2. 2. Provide insight in important data gaps and bias in current burden estimates to provide a framework for future burden studies and inform IMI’s strategical research agenda.

  3. 3. Create a dedicated data repository within the existing EPI-Net structure (

Academic Lead:  Prof. Stephan Harbarth, UNIGE: Dr. Stephan Harbarth is a well-known infectious disease epidemiologist with extensive research experience in the field of antimicrobial use and resistance, as well as clinical epidemiology and randomized clinical trials. Dr. Harbarth completed his master’s degree in epidemiology at Harvard University in Cambridge, Massachusetts and his work has garnered several awards. Currently, he is the principal investigator coordinating or participating in several international projects financed by the EC and other funding agencies. He is WP leader in COMBACTE for WP4 (STAT-Net), in ECRAID-Base (STAT-Net), as well as past academic coordinator of EU-funded projects SATURN and DRIVE-AB. 


Lead: Dr. Marlieke de Kraker, HUG:  Dr. Marlieke de Kraker finalized her MSc degree in Infectious Diseases Epidemiology at the Radboud University Nijmegen, the Netherlands. She was part of the Management Team of the European Antimicrobial Resistance Surveillance System at the Netherlands’ Institute for Public health and the Environment for 8 years, where she also earned her PhD on burden of AMR in 2012. She currently works for the Geneva University Hospitals and the WHO collaborating Centre on Patient Safety and Antimicrobial resistance, where she contributes to different European projects that aim to maintain and improve accessibility to effective antibiotics (COMBACTE, Ecraid), as well as projects focused on the burden of AMR, including MBIRA, GAP-ONE, and PrIMAVeRa, where she leads WP1. 


Industry Lead:  Dr. Venanzio Vella, GSK: Dr. Venanzio Vella earned his MD, MSc and PhD in Epidemiology from the London School of Hygiene, and MSc in Health Economics from the University of York, UK. He is the senior epidemiologist lead at GSK Vaccines in Siena since 2016. After first experiences as health specialist for WHO, UNICEF and the World Bank, he worked as an epidemiologist for Ministries and Public Health Institutes in several countries before joining Imperial College and later GSK. He will be the EFPIA lead for work packages 1 and 5.

bottom of page